Abstract
A 75-year-old man admitted with IgG λ-type myeloma with creatinine level of 2.3 mg/dL. Serum lactate dehydrogenase level and platelet count were normal. Urinalysis demonstrated massive proteinuria dominated by albuminuria. Weekly bortezomib and dexamethasone therapy were started to treat myeloma but failed to be continued because of rapid deterioration of renal function and increase in proteinuria 1 week after the treatment. His renal function exacerbated to require hemodialysis for a month. There was no clinical evidence of tumor lysis syndrome or thrombocytopenia throughout the course of his acute kidney injury (AKI). After he became dialysis independent, a renal biopsy was performed to clarify myeloma-related renal involvement and the cause of AKI. As a result, IgG2-λ monoclonal immunoglobulin deposition disease (MIDD) and severe endothelial injury were revealed. There was no evidence of cast nephropathy. Bortezomib-induced glomerular microangiopathy (GMA) superimposed on MIDD. Bortezomib has a potential risk to cause drug-induced GMA without systemic thrombotic microangiopathy, in which vascular endothelial growth factor-nuclear factor-κ B pathway could be involved. This is the first case of biopsy-proven bortezomib-induced GMA. If proteinuria (mainly albuminuria) increases after using bortezomib, GMA should be suspected as an adverse effect of bortezomib even absent of clinical signs of systemic thrombotic microangiopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–57.
Yui JC, Keer JV, Weiss BM, Waxman AJ, Palmer MB, D’Agati VD, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91(9):E348–52.
Keer JV, Delforge M, Dierickx D, Peerlinck K, Lerut E, Spranogers B. Renal thrombotic microangiopathy associated with the use of bortezomib in a patient with multiple myeloma [published online ahead of print May 16, 2016]. Case Report Hematol. https://doi.org/10.1155/2016/6020691.
Fonseca NM, Cardoso F, Monteiro M, Góis M, Sousa H, Fidalgo T, et al. A case of bortezomib-associated thrombotic microangiopathy in multiple myeloma [published online ahead of print Dec 26, 2019]. J Onco-Nephrol. https://doi.org/10.1177/2399369319894343.
Pfister F, Amann K, Daniel C, Klewer M, Büttner A, Büttner-Herold M. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73(6):990–1001.
Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684–700.
Lodhi A, Kumar A, Saqlain MU, Suneja M. Thrombotic microangiopathy associated with proteasome inhibitor. Clin Kidney J. 2015;8(5):632–6.
Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsy. Am J Kidney Dis. 2012;59(6):786–94.
Yui JC, Garceau D, Jhaveri KD, Wanchoo R, Bijol V, Glezerman I, et al. Monoclonal gammopathy-associated thrombotic microangiopathy. Am J Hematol. 2019;94(10):E250-253.
Navis GJ, Dullaart RPF, Vellenga E, Elema JD, de Jong PE. Renal disease in POEMS syndrome: report on a case and review of the literature. Nephrol Dial Transpl. 1994;9(10):1477–81.
Nakamura Y, Nishimura M, Terano T, McNamara KM, Sasano H, Kurosu A, et al. A patient with POEMS syndrome: the pathology of glomerular microangiopathy. Tohoku J Exp Med. 2013;231(3):229–34.
Sanada S, Ookawara S, Karube H, Shindo T, Goto T, Nakamichi T, et al. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. Am J Kidney Dis. 2006;47(4):672–9.
Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996;347(9002):702.
Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–87.
Lenug N, Gertz M, Kyle A, Fervenza FC, Irazabal MV, Eirin A, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol. 2012;7(12):1964–8.
Acknowledgements
The authors would like to extend their special thanks to Shin Onodera for his excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no relevant financial interests.
Ethical approval
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
Informed consent was obtained from the patient.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mizuno, S., Kitayama, C., Sanada, S. et al. Bortezomib-induced glomerular microangiopathy complicated with monoclonal immunoglobulin deposition disease. CEN Case Rep 10, 537–542 (2021). https://doi.org/10.1007/s13730-021-00603-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-021-00603-z